# Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

> **NCT01090466** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cardiff University** · enrollment: 15 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** temsirolimus
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01090466
- **Lead sponsor:** Cardiff University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2016-03-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090466, "Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01090466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*